25 XP   0   0   10

Humanigen Inc
Buy, Hold or Sell?

Let's analyse Humanigen together

PenkeI guess you are interested in Humanigen Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Humanigen Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Humanigen Inc

I send you an email if I find something interesting about Humanigen Inc.

Quick analysis of Humanigen (30 sec.)










What can you expect buying and holding a share of Humanigen? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.39
Expected worth in 1 year
$-1.17
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.78
Return On Investment
-775,176.4%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%

1. Valuation of Humanigen (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-14.33 - $-5.49

Total Value Per Share

$-14.73 - $-5.88

2. Growth of Humanigen (5 min.)




Is Humanigen growing?

Current yearPrevious yearGrowGrow %
How rich?-$46.7m-$23.6m-$23m-49.3%

How much money is Humanigen making?

Current yearPrevious yearGrowGrow %
Making money-$70.2m-$238.9m$168.6m240.1%
Net Profit Margin-2,793.9%-6,645.7%--

How much money comes from the company's main activities?

3. Financial Health of Humanigen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1000 / 1031

Most Revenue
#421 / 1031

Most Profit
#957 / 1031

Most Efficient
#885 / 1031

What can you expect buying and holding a share of Humanigen? (5 min.)

Welcome investor! Humanigen's management wants to use your money to grow the business. In return you get a share of Humanigen.

What can you expect buying and holding a share of Humanigen?

First you should know what it really means to hold a share of Humanigen. And how you can make/lose money.

Speculation

The Price per Share of Humanigen is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Humanigen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Humanigen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.39. Based on the TTM, the Book Value Change Per Share is $-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Humanigen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.59-589,838.8%-0.59-589,838.8%-1.99-1,987,311.1%-0.70-703,258.3%-0.49-489,628.8%
Usd Book Value Change Per Share-0.19-193,794.1%-0.19-193,794.1%-0.58-581,399.1%-0.04-37,670.5%0.0440,459.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-193,794.1%-0.19-193,794.1%-0.58-581,399.1%-0.04-37,670.5%0.0440,459.4%
Usd Price Per Share0.12-0.12-3.72-4.51-3.30-
Price to Earnings Ratio-0.20--0.20--1.87--7.59--7.53-
Price-to-Total Gains Ratio-0.62--0.62--6.40-4.72-2.45-
Price to Book Ratio-0.31--0.31--18.70-2.48-10.85-
Price-to-Total Gains Ratio-0.62--0.62--6.40-4.72-2.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.19-0.04
Usd Total Gains Per Share-0.19-0.04
Gains per Quarter (10000000 shares)-1,937,940.88-376,704.74
Gains per Year (10000000 shares)-7,751,763.52-1,506,818.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-7751764-77517740-1506819-1506829
20-15503527-155035380-3013638-3013648
30-23255291-232553020-4520457-4520467
40-31007054-310070660-6027276-6027286
50-38758818-387588300-7534095-7534105
60-46510581-465105940-9040914-9040924
70-54262345-542623580-10547733-10547743
80-62014108-620141220-12054552-12054562
90-69765872-697658860-13561371-13561381
100-77517635-775176500-15068189-15068200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.014.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.01.030.0%3.09.02.021.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.014.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.01.030.0%3.09.02.021.4%

Fundamentals of Humanigen

About Humanigen Inc

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Fundamental data was last updated by Penke on 2024-03-20 20:00:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Humanigen Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Humanigen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • A Net Profit Margin of -2,793.9% means that $-27.94 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Humanigen Inc:

  • The MRQ is -2,793.9%. The company is making a huge loss. -2
  • The TTM is -2,793.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,793.9%TTM-2,793.9%0.0%
TTM-2,793.9%YOY-6,645.7%+3,851.8%
TTM-2,793.9%5Y-7,713.0%+4,919.1%
5Y-7,713.0%10Y-13,390.1%+5,677.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,793.9%-171.8%-2,622.1%
TTM-2,793.9%-205.8%-2,588.1%
YOY-6,645.7%-262.1%-6,383.6%
5Y-7,713.0%-455.6%-7,257.4%
10Y-13,390.1%-589.0%-12,801.1%
1.1.2. Return on Assets

Shows how efficient Humanigen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • -627.4% Return on Assets means that Humanigen generated $-6.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Humanigen Inc:

  • The MRQ is -627.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -627.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-627.4%TTM-627.4%0.0%
TTM-627.4%YOY-336.2%-291.2%
TTM-627.4%5Y-839.8%+212.4%
5Y-839.8%10Y-629.2%-210.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-627.4%-12.5%-614.9%
TTM-627.4%-12.2%-615.2%
YOY-336.2%-11.2%-325.0%
5Y-839.8%-13.4%-826.4%
10Y-629.2%-14.7%-614.5%
1.1.3. Return on Equity

Shows how efficient Humanigen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • 0.0% Return on Equity means Humanigen generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Humanigen Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-39.9%+39.9%
5Y-39.9%10Y-165.8%+125.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM--15.7%+15.7%
YOY--13.9%+13.9%
5Y-39.9%-18.3%-21.6%
10Y-165.8%-19.2%-146.6%

1.2. Operating Efficiency of Humanigen Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Humanigen is operating .

  • Measures how much profit Humanigen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • An Operating Margin of -2,716.9% means the company generated $-27.17  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Humanigen Inc:

  • The MRQ is -2,716.9%. The company is operating very inefficient. -2
  • The TTM is -2,716.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,716.9%TTM-2,716.9%0.0%
TTM-2,716.9%YOY-6,474.9%+3,757.9%
TTM-2,716.9%5Y-7,492.1%+4,775.1%
5Y-7,492.1%10Y-13,032.9%+5,540.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,716.9%-299.1%-2,417.8%
TTM-2,716.9%-210.1%-2,506.8%
YOY-6,474.9%-279.7%-6,195.2%
5Y-7,492.1%-459.9%-7,032.2%
10Y-13,032.9%-596.9%-12,436.0%
1.2.2. Operating Ratio

Measures how efficient Humanigen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 28.17 means that the operating costs are $28.17 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Humanigen Inc:

  • The MRQ is 28.169. The company is inefficient in keeping operating costs low. -1
  • The TTM is 28.169. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ28.169TTM28.1690.000
TTM28.169YOY65.749-37.579
TTM28.1695Y75.521-47.351
5Y75.52110Y223.233-147.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.1692.861+25.308
TTM28.1693.193+24.976
YOY65.7493.615+62.134
5Y75.5215.560+69.961
10Y223.2337.396+215.837

1.3. Liquidity of Humanigen Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Humanigen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.20 means the company has $0.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Humanigen Inc:

  • The MRQ is 0.198. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.198. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.198TTM0.1980.000
TTM0.198YOY1.033-0.835
TTM0.1985Y0.952-0.755
5Y0.95210Y1.821-0.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1983.986-3.788
TTM0.1984.440-4.242
YOY1.0335.552-4.519
5Y0.9526.158-5.206
10Y1.8216.492-4.671
1.3.2. Quick Ratio

Measures if Humanigen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • A Quick Ratio of 0.18 means the company can pay off $0.18 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Humanigen Inc:

  • The MRQ is 0.181. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.181. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.181TTM0.1810.000
TTM0.181YOY1.019-0.838
TTM0.1815Y0.925-0.745
5Y0.92510Y2.070-1.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1813.638-3.457
TTM0.1814.168-3.987
YOY1.0195.515-4.496
5Y0.9256.012-5.087
10Y2.0706.209-4.139

1.4. Solvency of Humanigen Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Humanigen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Humanigen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 5.18 means that Humanigen assets are financed with 517.7% credit (debt) and the remaining percentage (100% - 517.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Humanigen Inc:

  • The MRQ is 5.177. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 5.177. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ5.177TTM5.1770.000
TTM5.177YOY1.333+3.844
TTM5.1775Y8.428-3.251
5Y8.42810Y5.934+2.494
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1770.335+4.842
TTM5.1770.330+4.847
YOY1.3330.267+1.066
5Y8.4280.367+8.061
10Y5.9340.378+5.556
1.4.2. Debt to Equity Ratio

Measures if Humanigen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Humanigen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Humanigen Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.100-0.100
5Y0.10010Y0.343-0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY-0.334-0.334
5Y0.1000.429-0.329
10Y0.3430.476-0.133

2. Market Valuation of Humanigen Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Humanigen generates.

  • Above 15 is considered overpriced but always compare Humanigen to the Biotechnology industry mean.
  • A PE ratio of -0.20 means the investor is paying $-0.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Humanigen Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.203. Based on the earnings, the company is expensive. -2
  • The TTM is -0.203. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.203+0.203
MRQ-0.203TTM-0.2030.000
TTM-0.203YOY-1.872+1.668
TTM-0.2035Y-7.587+7.383
5Y-7.58710Y-7.527-0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.643+2.643
MRQ-0.203-2.418+2.215
TTM-0.203-2.742+2.539
YOY-1.872-4.123+2.251
5Y-7.587-6.257-1.330
10Y-7.527-6.478-1.049
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Humanigen Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.186. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.186. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.186+0.186
MRQ-0.186TTM-0.1860.000
TTM-0.186YOY-2.407+2.221
TTM-0.1865Y-12.070+11.884
5Y-12.07010Y-9.872-2.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.244+3.244
MRQ-0.186-2.939+2.753
TTM-0.186-3.478+3.292
YOY-2.407-5.592+3.185
5Y-12.070-8.473-3.597
10Y-9.872-8.881-0.991
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Humanigen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.31 means the investor is paying $-0.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Humanigen Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is -0.306. Based on the equity, the company is expensive. -2
  • The TTM is -0.306. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.306+0.305
MRQ-0.306TTM-0.3060.000
TTM-0.306YOY-18.701+18.395
TTM-0.3065Y2.483-2.789
5Y2.48310Y10.853-8.370
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0002.124-2.124
MRQ-0.3062.041-2.347
TTM-0.3062.118-2.424
YOY-18.7012.915-21.616
5Y2.4833.682-1.199
10Y10.8534.114+6.739
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Humanigen Inc.

3.1. Institutions holding Humanigen Inc

Institutions are holding 0.491% of the shares of Humanigen Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Triumph Capital Management0.014301700000
2023-09-30CapTrust Financial Advisors000-61000-100
2023-09-30State Street Corporation000-188676-100
2023-09-30Wells Fargo & Co000-3780-100
2023-09-30Tower Research Capital LLC000-46289-100
2023-12-31DAYMARK WEALTH PARTNERS LLC000-12500-100
2023-09-30Northern Trust Corp000-140542-100
2023-09-30Onyx Bridge Wealth Group LLC000-28037-100
2023-09-30Valeo Financial Advisors, LLC000-30000-100
2023-09-30Guardian Wealth Management, Inc.000-128-100
2023-09-30Citadel Advisors Llc000-24586-100
2023-12-31Atlantic Trust Group, LLC000-10000-100
2023-09-30Morgan Stanley - Brokerage Accounts000-62003-100
2023-09-30Valley National Advisers Inc000-4-100
2023-09-30Two Sigma Investments LLC000-153889-100
2023-09-30Advisor Group Holdings, Inc.000-11950-100
2023-09-30HRT FINANCIAL LLC000-16469-100
2023-09-30AE Wealth Management LLC000-39250-100
2023-09-30HARBOUR INVESTMENTS, INC.000-75-100
2023-09-30Royal Bank of Canada000-10940-100
Total 0.0143017000-840118-4,941.9%

3.2. Funds holding Humanigen Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-11-30Guggenheim Active Allocation Fund0.0002028400
2023-11-30BMO MSCI Genomic Innovation ETF0.0001080800
Total 0.00030364+80+22.0%

3.3. Insider Transactions

Insiders are holding 10.351% of the shares of Humanigen Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-20Dale ChappellBUY5454882.23
2022-05-18Dale ChappellBUY1737001.96
2022-03-11Dale ChappellBUY10000003
2022-03-08Adrian KilcoyneBUY70002.53
2022-03-02Cameron DurrantBUY400002.34
2022-03-02Edward P JordanBUY125002.32
2021-08-11Dale ChappellSELL10964717.07
2021-07-28Dale ChappellSELL969217.04
2021-07-23Dale ChappellSELL558417.04
2021-07-21Dale ChappellSELL13276417.14
2021-07-14Dale ChappellSELL1517717.06
2021-07-08Dale ChappellSELL4801017.17
2021-06-25Dale ChappellSELL100000017.8
2021-06-23Dale ChappellSELL13312618.28
2021-06-18Dale ChappellSELL40248018.5
2021-06-16Dale ChappellSELL15848619.41
2021-06-14Cameron DurrantSELL8144120.64
2021-06-08Edward P JordanSELL1470020.08
2021-06-04Dale ChappellSELL12708418.46
2021-06-02Dale ChappellSELL7612619.01

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Humanigen Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.194-0.1940%-0.581+200%-0.038-81%0.040-579%
Book Value Per Share---0.393-0.3930%-0.199-49%-0.080-80%0.021-1975%
Current Ratio--0.1980.1980%1.033-81%0.952-79%1.821-89%
Debt To Asset Ratio--5.1775.1770%1.333+288%8.428-39%5.934-13%
Debt To Equity Ratio----0%-0%0.100-100%0.343-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.590-0.5900%-1.987+237%-0.703+19%-0.490-17%
Free Cash Flow Per Share---0.644-0.6440%-1.546+140%-0.572-11%-0.411-36%
Free Cash Flow To Equity Per Share---0.503-0.5030%0.019-2727%0.016-3289%-0.031-94%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.490--------
Intrinsic Value_10Y_min---14.333--------
Intrinsic Value_1Y_max---0.442--------
Intrinsic Value_1Y_min---1.065--------
Intrinsic Value_3Y_max---1.410--------
Intrinsic Value_3Y_min---3.541--------
Intrinsic Value_5Y_max---2.478--------
Intrinsic Value_5Y_min---6.370--------
Market Cap11908.000-119900%14289600.00014289600.0000%442977600.000-97%536514940.000-97%392725840.000-96%
Net Profit Margin---27.939-27.9390%-66.457+138%-77.130+176%-133.901+379%
Operating Margin---27.169-27.1690%-64.749+138%-74.921+176%-130.329+380%
Operating Ratio--28.16928.1690%65.749-57%75.521-63%223.233-87%
Pb Ratio0.000+100%-0.306-0.3060%-18.701+6020%2.483-112%10.853-103%
Pe Ratio0.000+100%-0.203-0.2030%-1.872+820%-7.587+3629%-7.527+3600%
Price Per Share0.000-119900%0.1200.1200%3.720-97%4.506-97%3.298-96%
Price To Free Cash Flow Ratio0.000+100%-0.186-0.1860%-2.407+1192%-12.070+6379%-9.872+5199%
Price To Total Gains Ratio-0.001+100%-0.619-0.6190%-6.398+933%4.716-113%2.455-125%
Quick Ratio--0.1810.1810%1.019-82%0.925-80%2.070-91%
Return On Assets---6.274-6.2740%-3.362-46%-8.398+34%-6.292+0%
Return On Equity----0%-0%-0.3990%-1.6580%
Total Gains Per Share---0.194-0.1940%-0.581+200%-0.038-81%0.040-579%
Usd Book Value---46765000.000-46765000.0000%-23688000.000-49%-9467200.000-80%2494100.000-1975%
Usd Book Value Change Per Share---0.194-0.1940%-0.581+200%-0.038-81%0.040-579%
Usd Book Value Per Share---0.393-0.3930%-0.199-49%-0.080-80%0.021-1975%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.590-0.5900%-1.987+237%-0.703+19%-0.490-17%
Usd Free Cash Flow---76698000.000-76698000.0000%-184045000.000+140%-68165200.000-11%-48901900.000-36%
Usd Free Cash Flow Per Share---0.644-0.6440%-1.546+140%-0.572-11%-0.411-36%
Usd Free Cash Flow To Equity Per Share---0.503-0.5030%0.019-2727%0.016-3289%-0.031-94%
Usd Market Cap11908.000-119900%14289600.00014289600.0000%442977600.000-97%536514940.000-97%392725840.000-96%
Usd Price Per Share0.000-119900%0.1200.1200%3.720-97%4.506-97%3.298-96%
Usd Profit---70238000.000-70238000.0000%-238913000.000+240%-84733800.000+21%-59635800.000-15%
Usd Revenue--2514000.0002514000.0000%3595000.000-30%1284200.000+96%646500.000+289%
Usd Total Gains Per Share---0.194-0.1940%-0.581+200%-0.038-81%0.040-579%
 EOD+2 -6MRQTTM+0 -0YOY+15 -165Y+12 -2010Y+9 -23

4.2. Fundamental Score

Let's check the fundamental score of Humanigen Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than0-27.939
Operating Margin (MRQ)Greater than0-27.169
Quick Ratio (MRQ)Greater than10.181
Current Ratio (MRQ)Greater than10.198
Debt to Asset Ratio (MRQ)Less than15.177
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-6.274
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Humanigen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.535
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Income Tax Expense  1791,1701,349-131,3369282,264-2,756-492



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,195
Total Liabilities57,960
Total Stockholder Equity-46,765
 As reported
Total Liabilities 57,960
Total Stockholder Equity+ -46,765
Total Assets = 11,195

Assets

Total Assets11,195
Total Current Assets11,105
Long-term Assets90
Total Current Assets
Cash And Cash Equivalents 10,155
Other Current Assets 950
Total Current Assets  (as reported)11,105
Total Current Assets  (calculated)11,105
+/-0
Long-term Assets
Long-term Assets Other 90
Long-term Assets  (as reported)90
Long-term Assets  (calculated)90
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities56,194
Long-term Liabilities1,766
Total Stockholder Equity-46,765
Total Current Liabilities
Accounts payable 40,520
Other Current Liabilities 14,791
Total Current Liabilities  (as reported)56,194
Total Current Liabilities  (calculated)55,311
+/- 883
Long-term Liabilities
Long-term Liabilities  (as reported)1,766
Long-term Liabilities  (calculated)0
+/- 1,766
Total Stockholder Equity
Common Stock119
Retained Earnings -681,809
Other Stockholders Equity 634,925
Total Stockholder Equity (as reported)-46,765
Total Stockholder Equity (calculated)-46,765
+/-0
Other
Capital Stock119
Cash and Short Term Investments 10,155
Common Stock Shares Outstanding 59,487
Current Deferred Revenue883
Liabilities and Stockholders Equity 11,195
Net Debt -10,155
Net Invested Capital -46,765
Net Working Capital -45,089



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
> Total Assets 
0
35,984
19,347
24,539
78,704
42,977
11,146
11,146
1,670
1,370
523
68,302
71,061
11,195
11,19571,06168,3025231,3701,67011,14611,14642,97778,70424,53919,34735,9840
   > Total Current Assets 
0
35,315
18,604
21,256
77,722
42,245
10,394
10,394
1,550
1,299
452
68,212
70,971
11,105
11,10570,97168,2124521,2991,55010,39410,39442,24577,72221,25618,60435,3150
       Cash And Cash Equivalents 
0
8,902
3,338
10,947
54,220
10,923
8,431
8,431
737
814
143
67,737
70,016
10,155
10,15570,01667,7371438147378,4318,43110,92354,22010,9473,3388,9020
       Short-term Investments 
0
24,852
14,509
9,351
22,511
29,790
0
0
0
0
0
0
0
0
0000000029,79022,5119,35114,50924,8520
       Net Receivables 
0
678
238
87
44
0
0
0
0
0
0
0
0
0
00000000044872386780
       Other Current Assets 
0
890
510
870
950
31,322
1,963
1,963
813
485
309
475
955
950
9509554753094858131,9631,96331,3229508705108900
   > Long-term Assets 
0
669
743
3,283
982
732
752
752
120
71
71
90
90
90
90909071711207527527329823,2837436690
       Property Plant Equipment 
0
447
427
230
276
414
288
288
19
0
0
0
0
0
00000192882884142762304274470
       Intangible Assets 
0
0
0
45
0
0
0
0
0
0
0
20
0
0
0020000000045000
       Other Assets 
0
222
316
3,053
706
318
464
101
101
71
71
70
90
0
0907071711011014643187063,0533162220
> Total Liabilities 
0
106,387
91,692
119,483
18,168
18,364
5,414
5,414
26,006
9,480
14,841
22,757
94,749
57,960
57,96094,74922,75714,8419,48026,0065,4145,41418,36418,168119,48391,692106,3870
   > Total Current Liabilities 
0
19,194
8,108
7,217
11,382
18,053
3,600
7,824
24,655
8,263
13,594
20,415
68,725
56,194
56,19468,72520,41513,5948,26324,6557,8243,60018,05311,3827,2178,10819,1940
       Short-term Debt 
0
-15,694
-5,628
0
3,182
10,928
1,200
3,016
18,018
2,278
5,240
5,240
0
0
005,2405,2402,27818,0183,0161,20010,9283,1820-5,628-15,6940
       Short Long Term Debt 
0
0
0
0
0
10,928
1,200
3,016
18,018
2,278
5,240
0
0
0
0005,2402,27818,0183,0161,20010,92800000
       Accounts payable 
0
1,174
266
2,448
3,197
1,822
2,800
4,072
3,330
2,856
5,046
13,078
44,698
40,520
40,52044,69813,0785,0462,8563,3304,0722,8001,8223,1972,4482661,1740
       Other Current Liabilities 
0
18,020
7,840
4,769
4,998
89
0
736
3,307
3,129
3,308
5,463
19,882
14,791
14,79119,8825,4633,3083,1293,3077360894,9984,7697,84018,0200
   > Long-term Liabilities 
0
87,193
83,584
112,266
6,786
311
5,414
5,414
1,351
1,217
1,247
2,342
26,024
1,766
1,76626,0242,3421,2471,2171,3515,4145,4143116,786112,26683,58487,1930
       Long term Debt Total 
0
0
0
9,826
6,786
0
0
1,273
1,351
1,217
1,247
0
25,006
0
025,00601,2471,2171,3511,273006,7869,826000
       Warrants
0
0
0
102,023
0
0
0
0
0
0
0
0
0
0
0000000000102,023000
       Other Liabilities 
0
4,015
406
417
0
311
614
1,273
1,351
0
0
2,342
1,018
0
01,0182,342001,3511,27361431104174064,0150
       Deferred Long Term Liability 
0
0
0
62
0
311
0
0
0
0
0
2,342
1,018
0
01,0182,34200000311062000
> Total Stockholder Equity
0
-70,403
-72,345
-94,944
60,536
24,613
5,732
5,732
-24,336
-8,110
-14,318
45,545
-23,688
-46,765
-46,765-23,68845,545-14,318-8,110-24,3365,7325,73224,61360,536-94,944-72,345-70,4030
   Common Stock
0
2
2
2
33
33
4
4
15
110
114
52
64
119
1196452114110154433332220
   Retained Earnings Total Equity0-611,079-374,430-284,895-274,601-262,597-240,610-213,591-178,213-140,215-98,267000
   Accumulated Other Comprehensive Income 
0
-3
-1
4
3
-8
-231
-148
0
0
0
0
0
0
000000-148-231-834-1-30
   Capital Surplus 
0
0
0
3,317
200,715
202,801
219,319
236,216
238,246
266,381
270,463
419,923
587,327
0
0587,327419,923270,463266,381238,246236,216219,319202,801200,7153,317000
   Treasury Stock00000000000000
   Other Stockholders Equity 
0
2,130
2,416
-98,706
200,723
202,801
0
219,319
238,246
266,381
270,463
419,923
587,327
634,925
634,925587,327419,923270,463266,381238,246219,3190202,801200,723-98,7062,4162,1300



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue2,514
Cost of Revenue-0
Gross Profit2,5142,514
 
Operating Income (+$)
Gross Profit2,514
Operating Expense-70,818
Operating Income-68,304-68,304
 
Operating Expense (+$)
Research Development55,210
Selling General Administrative15,608
Selling And Marketing Expenses0
Operating Expense70,81870,818
 
Net Interest Income (+$)
Interest Income0
Interest Expense-2,918
Other Finance Cost-0
Net Interest Income-2,918
 
Pretax Income (+$)
Operating Income-68,304
Net Interest Income-2,918
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-70,730-65,878
EBIT - interestExpense = -71,222
-70,730
-67,320
Interest Expense2,918
Earnings Before Interest and Taxes (EBIT)-68,304-67,812
Earnings Before Interest and Taxes (EBITDA)-67,812
 
After tax Income (+$)
Income Before Tax-70,730
Tax Provision-0
Net Income From Continuing Ops-70,730-70,730
Net Income-70,238
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses70,818
Total Other Income/Expenses Net-2,4262,918
 

Technical Analysis of Humanigen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Humanigen. The general trend of Humanigen is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Humanigen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Humanigen Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Humanigen Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Humanigen Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Humanigen Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Humanigen Inc. The current macd is -0.000056.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Humanigen price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Humanigen. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Humanigen price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Humanigen Inc Daily Moving Average Convergence/Divergence (MACD) ChartHumanigen Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Humanigen Inc. The current adx is 38.33.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Humanigen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Humanigen Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Humanigen Inc. The current sar is 0.00224025.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Humanigen Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Humanigen Inc. The current rsi is 41.54. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Humanigen Inc Daily Relative Strength Index (RSI) ChartHumanigen Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Humanigen Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Humanigen price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Humanigen Inc Daily Stochastic Oscillator ChartHumanigen Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Humanigen Inc. The current cci is -47.61904762.

Humanigen Inc Daily Commodity Channel Index (CCI) ChartHumanigen Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Humanigen Inc. The current cmo is -15.33168255.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Humanigen Inc Daily Chande Momentum Oscillator (CMO) ChartHumanigen Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Humanigen Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Humanigen Inc Daily Williams %R ChartHumanigen Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Humanigen Inc.

Humanigen Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Humanigen Inc. The current atr is 0.000074.

Humanigen Inc Daily Average True Range (ATR) ChartHumanigen Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Humanigen Inc. The current obv is -295,194,947.

Humanigen Inc Daily On-Balance Volume (OBV) ChartHumanigen Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Humanigen Inc. The current mfi is 0.0000.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Humanigen Inc Daily Money Flow Index (MFI) ChartHumanigen Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Humanigen Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-10-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-10-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-10-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-10-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Humanigen Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Humanigen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.535
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Humanigen with someone you think should read this too:
  • Are you bullish or bearish on Humanigen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Humanigen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Humanigen Inc

I send you an email if I find something interesting about Humanigen Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Humanigen Inc.

Receive notifications about Humanigen Inc in your mailbox!